The Claim
Urolithin A enhances relaxation and contraction kinetics in engineered human heart tissue through activation of PKGIα.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Urolithin A increases the speed of relaxation and contraction in human heart tissue grown in the lab by activating the protein PKGIα.
See the scientific wording
Urolithin A enhances relaxation and contraction kinetics in engineered human heart tissue by activating PKGIα, suggesting potential translational relevance to human cardiac physiology.
Urolithin A chemically modifies a specific spot on a heart protein called PKGIα, which turns the protein on. This activated protein then adds a chemical tag to another protein that controls calcium removal from heart cells. When calcium is removed faster, the heart muscle relaxes more quickly after contracting, allowing the heart to fill and pump more efficiently.
What the research says
1 studyStudy: Targeting Cysteine 42 in PKGIa limits diastolic dysfunction in HFpEF
In lab-grown human heart tissue, urolithin A made the heart cells beat more efficiently by activating a specific protein (PKGIα), just like it did in mice. This suggests it could help human hearts work better.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.